Novel Approaches to Treat Refractory Haematological Malignancies

First-in-human RNA polymerase I transcription inhibitor CX-5461 in patients with advanced hematologic cancers: Results of a phase I dose-escalation study

A Khot, N Brajanovski, DP Cameron, N Hein, KH Maclachlan, E Sanij, J Lim, J Soong, E Link, P Blombery, ER Thompson, A Fellowes, KE Sheppard, GA McArthur, RB Pearson, RD Hannan, G Poortinga, SJ Harrison

2019-08-01

RNA polymerase I (Pol I) transcription of ribosomal RNA genes (rDNA) is tightly regulated downstream of oncogenic pathways, and it..

Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population

N Hein, DP Cameron, KM Hannan, NYN Nguyen, CY Fong, J Sornkom, M Wall, M Pavy, C Cullinane, J Diesch, JR Devlin, AJ George, E Sanij, J Quin, G Poortinga, I Verbrugge, A Baker, D Drygin, SJ Harrison, JD Rozario

2017-05-25

Despite the development of novel drugs, the prospects for many patients with acute myeloid leukemia (AML) remain dismal. This stud..